Tag:
Vytorin
Latest Headlines
Latest Headlines
Vytorin outcomes study barrels on without a peek
The Vytorin outcomes study is going ahead without a hint about how things are faring. The safety monitors of Improve-It, which is testing Merck's ( $MRK ) cholesterol-fighting drug Vytorin, say no new dangers have cropped up among the 18,000 patients enrolled.
Merck's new cholesterol combo faces delay
Merck's ( $MRK ) bid to get a combination Zetia - Lipitor cholesterol pill on the market faces a new hurdle. The FDA wants to see more data on the pill. The company hopes ongoing studies will fill...
Merck's new label for Vytorin disappoints the analysts
The FDA approved a label change that recognizes how Vytorin can prevent heart problems among chronic kidney disease patients, butdidn't specifically give it an approval for that indication. Now Merck
FDA panel approves outcomes claim for Vytorin
The FDA advisory panel reviewing a new indication for Merck's ( $MRK ) cholesterol fighter Vytorin gave the drug a nod for preventing cardiovascular problems in patients with kidney disease, but voted
Vytorin cuts heart risks in kidney patients, FDA says
Merck ( $MRK ) is one step closer to a new indication for its blockbuster cholesterol-fighter Vytorin . In advance of an FDA advisory committee meeting Wednesday, agency reviewers released their
Merck blockbuster heart pill Vytorin plugged in FDA review
FDA staffers gave a thumbs up to Merck's blockbuster cholesterol drug Vytorin in patients with kidney disease, providing a boost to one of the drug giant's ( $MRK ) key pipeline programs ahead of an
Planned analysis for top Merck drug program runs into a delay
An interim analysis for one of Merck's ( $MRK ) top pipeline programs has been delayed by several months. Originally slated for late 2011, Merck now says the second interim analysis of IMPROVE-IT,
Teva, Merck agree to 2017 date for Vytorin copies
Teva Pharmaceutical Industries has agreed that it won't sell generic versions of Merck's ( $MRK ) cholesterol drugs Vytorin and Zetia until 2017, settling patent disputes between the two companies.
Merck, Teva near deal on generic Vytorin
Merck is close to resolving a patent dispute over its cholesterol combo drug Vytorin, court documents show. As Bloomberg reports, the company and its would-be generic rival Teva Pharmaceutical
Merck's ($MRK) Vytorin aids kidney patients, trial shows
Will a new indication reverse Vytorin's downward spiral? We may well get an opportunity to find out. In trial data presented over the weekend, the cholesterol drug beat placebo at preventing
